URL has been copied successfully!
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Gossamer announced on February 23, 2026, that its product candidate seralutinib failed to meet its …
Full story available on Benzinga.com
Please follow us:
This post was originally published here
